Paradigm Biopharmaceuticals Limited (ASX:PAR – Get Free Report) insider Paul Rennie bought 95,300 shares of Paradigm Biopharmaceuticals stock in a transaction that occurred on Tuesday, October 15th. The shares were acquired at an average price of A$0.21 ($0.14) per share, with a total value of A$20,108.30 ($13,405.53).
Paradigm Biopharmaceuticals Price Performance
The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.93 and a current ratio of 7.22.
Paradigm Biopharmaceuticals Company Profile
Read More
- Five stocks we like better than Paradigm Biopharmaceuticals
- Why Are Stock Sectors Important to Successful Investing?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Do ETFs Pay Dividends? What You Need to Know
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Differences Between Momentum Investing and Long Term Investing
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Paradigm Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paradigm Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.